CD19 and acute lymphoblastic leukemia: For relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) patients, although CR rate after initial anti-CD19 CAR-T therapy is higher than 70%, ~30 to 50% of these CR patients suffered disease relapse within 1 year of treatment (4).